

Administration Case Report With EXPAREL

This case report represents the individual experience of Dr Jacob Hutchins and is intended to demonstrate his methodology for using EXPAREL in a specific soft tissue surgery.

Pacira Pharmaceuticals, Inc. recognizes that there are alternative methodologies for administering local anesthetics, as well as individual patient considerations, when selecting the dose for a specific procedure.

EXPAREL is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.


CASE INFORMATION

Physician Name	Jacob Hutchins, MD
Affiliation	University of Minnesota Medical Center
Surgical Case Performed	Open hysterectomy
Inpatient or Outpatient Procedure	Inpatient

PATIENT CHARACTERISTICS

Gender	Female
Age	53 years of age
Patient History and Characteristics	Pelvic mass

PROCEDURAL DETAILS

Incision Size	Infraumbilical midline incision T10-L1
Preoperative Analgesics Used	50 mcg of fentanyl and 1 mg of midazolam administered in advance of the TAP procedure
Intraoperative Analgesics Used	450 mcg of fentanyl
Dose of EXPAREL and Total Volume Used	 <p>EXPAREL (266 mg) + Bupivacaine HCl 0.25% + Normal Saline = Total 60 mL</p>

TAP, transversus abdominis plane.

The recommended dose of EXPAREL is based on the size of the surgical site, the volume required to cover the area, and individual patient factors that may impact the safety of an amide local anesthetic. The maximum dose of EXPAREL should not exceed 266 mg.

EXPAREL can be administered unexpanded (20 mL) or expanded to increase volume up to a total of 300 mL (final concentration of 0.89 mg/mL [ie, 1:14 dilution by volume]) with normal (0.9%) saline or lactated Ringer's solution.


Bupivacaine HCl may be administered immediately before EXPAREL or admixed in the same syringe, as long as the ratio of the milligram dose of bupivacaine HCl to EXPAREL does not exceed 1:2. Admixing may impact the pharmacokinetic and/or physiochemical properties of EXPAREL, and this effect is concentration dependent. The toxic effects of these drugs are additive and their administration should be used with caution, including monitoring for neurological and cardiovascular effects related to local anesthetic systemic toxicity. Other than with bupivacaine, EXPAREL should not be admixed with other drugs prior to administration.

Please see Important Safety Information on reverse and refer to the accompanying full Prescribing Information before using EXPAREL for complete Dosage and Administration information.

INFILTRATION NOTES

- Prior to surgery, the patient was prepped with 2% chlorhexidine gluconate and 70% isopropyl alcohol
- When dry, an ultrasound-guided left classic TAP was performed with a 21-gauge 100-mm needle with a 30-degree bevel (see Figure 1)
- 2 mL of 0.25% bupivacaine with epinephrine 1:200,000 was used to confirm correct needle position beneath the fascia covering the transversus abdominis as well as to negate intravascular injection (see Figure 2)
- This was then followed by 30 mL of EXPAREL® (bupivacaine liposome injectable suspension) solution with aspiration every 5 mL increments (see Figure 3)
 - The TAP was confirmed during the entire injection with ultrasound
- This procedure was then performed on the right side

TAP, transversus abdominis plane.



EO, external oblique; IO, internal oblique; TA, transversus abdominis.

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia. Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation. If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine. EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL. EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks **other than interscalene brachial plexus nerve block**, or intravascular or intra-articular use. The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

Warnings and Precautions for Bupivacaine-Containing Products

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression. **Cardiovascular System Reactions:** Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias, sometimes leading to death. **Allergic Reactions:** Allergic-type reactions (eg, anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients. **Chondrolysis:** There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Disclosure: Dr Hutchins is a paid consultant for Pacira Pharmaceuticals, Inc.

This administration technique guide represents the individual capacity of Dr Jacob Hutchins and not the capacity of the University of Minnesota, UMP, or Fairview.